Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.
Brenda Luana Rocha Soares Menegat, Ana Luíza Rocha Soares Menegat, Maria Victória Ferreira Piccoli et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated neoadjuvant treatment regimens for early-stage triple-negative breast cancer (TNBC) across 37 studies involving 7683 patients. The analysis found that regimens including paclitaxel, carboplatin, and pembrolizumab significantly increased the rates of pathological complete response (pCR), with an odds ratio of 3.04 compared to standard regimens.
Key findings
- PA-based + carboplatin + pembrolizumab + cyclophosphamide achieved an OR of 3.04 for pCR.
- PA-based + carboplatin + veliparib + cyclophosphamide showed an OR of 2.67 for pCR.
- DA-based + cyclophosphamide + bevacizumab increased pCR with an OR of 1.67.
Why it matters
The findings highlight the potential of incorporating platinum agents, PARP inhibitors, and immune checkpoint inhibitors in neoadjuvant settings for TNBC, which may improve treatment outcomes and inform clinical decision-making.